Bristol-Myers Squibb Company (BMY) continues to attract the attention of investors, consistently ranking among the best
S&P 500 Dividend Stocks. Despite certain market fluctuations, the company’s stock has touched a
52-week high at $61.11 amid a market rally. The stock's durability can be attributed to the firm's
successful psoriatic arthritis trial and recent regulatory approvals of their new drugs such as
Opdivo Qvantig and
COBENFY, the latter being the first FDA-approved muscarinic agonist for schizophrenia treatment. Despite reporting
weak guidance and plans for
$2 billion in cost cuts by 2027, Bristol Myers continues to generate interest with its robust
balance sheet and commitment to research and development, particularly in the oncology field. Notably, Bristol Myers employees raised over $1 million for the
V Foundation for Cancer Research. Moving forward, the success of their
cancer immunotherapy and
ex vivo T-Cell therapies, expected to beat earnings estimates, will be critical for the company’s continued growth.
Bristol-Myers Squibb BMY News Analytics from Mon, 06 May 2024 07:00:00 GMT to Sat, 08 Mar 2025 19:22:02 GMT -
Rating 7
- Innovation 6
- Information 9
- Rumor -3
